These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 1095958

  • 21. [Prodectin treatment of partial hearing loss as a result of atherosclerosis].
    Smirnova NA, Timakov VA, Mikushkin MK.
    Vestn Otorinolaringol; 1982; (6):53-6. PubMed ID: 7179649
    [No Abstract] [Full Text] [Related]

  • 22. Results obtained with prodectin in arteriosclerotic arterial obliteration of the lower extremities.
    Hunyi L.
    Ther Hung; 1976; 24(2):67-71. PubMed ID: 982342
    [No Abstract] [Full Text] [Related]

  • 23. [Comparison of the effectiveness of anginin and stugeron treatment of cerebral arteriosclerosis].
    Sobczyk W, Kruszewska J, Szymchel J.
    Neurol Neurochir Pol; 1980; 14(2):183-9. PubMed ID: 6993976
    [Abstract] [Full Text] [Related]

  • 24. [Clinical and rheoencephalographical evaluation of prodectin in the treatment of cerebral arteriosclerosis].
    Wysocka-Bakowska MM.
    Neurol Neurochir Pol; 1981; 15(4):431-36. PubMed ID: 7035991
    [Abstract] [Full Text] [Related]

  • 25. Comparison of conservative (Prodectin) treatment and surgical intervention in arteriosclerotic obliterative diseases of the lower extremities.
    Hunyi L.
    Ther Hung; 1978; 26(2):77-80. PubMed ID: 684660
    [No Abstract] [Full Text] [Related]

  • 26. Partial suppression by pyridinolcarbamate of growth and necrosis of atherosclerotic lesions in swine subjected to an atherogenic regimen that produces advanced lesions.
    Lee WM, Lee KT, Thomas WA.
    Exp Mol Pathol; 1979 Feb; 30(1):85-93. PubMed ID: 421864
    [No Abstract] [Full Text] [Related]

  • 27. Pyridinolcarbamate in the long-term treatment of ischaemic heart disease.
    Gulyás A, Szám I.
    Ther Hung; 1976 Feb; 24(2):63-6. PubMed ID: 982341
    [No Abstract] [Full Text] [Related]

  • 28. [Study of pyridinolcarbamate in the treatment of diabetic angiopathies and atheromatous arteritis].
    Plauchu M, Bussy L, Rondelet J.
    Lyon Med; 1972 Feb 13; 227(3):271-7. PubMed ID: 5037162
    [No Abstract] [Full Text] [Related]

  • 29. [Changes of the electrophoretic tracing of the serum glycoproteins in diabetic subjects treated with pyridinolcarbamate].
    Notarbartolo A, Rini GB, Di Fede G.
    Boll Soc Ital Cardiol; 1973 Feb 13; 18(4):379-83. PubMed ID: 4807078
    [No Abstract] [Full Text] [Related]

  • 30. [Comparative double-blind study on the normolipemic effect of clofibrate and a clofibrate-mucopolysaccharide extract combination].
    Cagli V, Lillo V.
    Clin Ter; 1975 Oct 31; 75(2):153-69. PubMed ID: 132333
    [No Abstract] [Full Text] [Related]

  • 31. [Thermal test of reactive hyperemia: a propos of an objective study of pyridinol carbamate].
    Lauliac M.
    Phlebologie; 1978 Oct 31; 31(2):119-29. PubMed ID: 693585
    [Abstract] [Full Text] [Related]

  • 32. [Clinical and therapeutic evaluation of simfibrate compared toclofibrate in atherosclerotic patients].
    De Rosa G, Savi L, De Rosa E, Pola P, Boni P.
    Clin Ter; 1979 Feb 15; 88(3):267-79. PubMed ID: 376218
    [No Abstract] [Full Text] [Related]

  • 33. [The clofibrate-dipyridamole combination in the prevention and therapy of arteriosclerotic vascular disease and its complications].
    Cucinotta D, Ferretti PG, Daccò L, Mazzera F.
    G Clin Med; 1977 Feb 15; 58(11-12):475-86. PubMed ID: 608558
    [No Abstract] [Full Text] [Related]

  • 34. [Therapeutic effect of pyridylcarbinolic ester of clofibric acid on the changes of the lipid and fibrinolytic picture in arteriosclerotic patients].
    Rugginenti.
    Minerva Med; 1974 May 09; 65(35):1906-16. PubMed ID: 4601840
    [No Abstract] [Full Text] [Related]

  • 35. The effect of Prodectin (pyridinolcarbamate) treatment of the circulation rate in obliterating arterial diseases of the lower extremities.
    Fényes G, Gótzy G, Fehrentheil L.
    Ther Hung; 1975 May 09; 23(2):64-66. PubMed ID: 1188705
    [No Abstract] [Full Text] [Related]

  • 36. [Mechanism of action and clinical effectiveness of the new Soviet-made drug parmidin in the treatment of arteriosclerosis and ischemic heart disease].
    Kukes VG, Mashkovskiĭ MD, Paskhina TS, Borisov VG, Shvarts GIa.
    Kardiologiia; 1978 Oct 09; 18(10):61-8. PubMed ID: 213636
    [Abstract] [Full Text] [Related]

  • 37. Antiatherogenic effect of pyridinolcarbamate (prodectin). Experimental study.
    Orbetzova V, Jurukova Z, Orbetzova M.
    Artery; 1980 Oct 09; 8(6):560-9. PubMed ID: 7259535
    [Abstract] [Full Text] [Related]

  • 38. [Changes of the blood kallikrein-kinin system in patients with diffuse toxic goiter under the influence of thyrostatic therapy and prodectin].
    Matiashina GI.
    Vrach Delo; 1989 Apr 09; (4):31-3. PubMed ID: 2474220
    [Abstract] [Full Text] [Related]

  • 39. [Clinical evaluation of the therapeutic activity of the beta-pyridyl-carbinolic ester of clofibric acid].
    Silingardi V, Renzi R, Mora A, Di Prisco AU.
    Minerva Med; 1973 Mar 21; 64(16):751-69. PubMed ID: 4579325
    [No Abstract] [Full Text] [Related]

  • 40. A clinical trial with pyridinolcarbamate in the treatment of patients with obstructive diseases of the peripheral arteries.
    Zelikovsky A, Urca I, Shaklai M, de Vries A.
    Jpn Heart J; 1973 Jan 21; 14(1):12-21. PubMed ID: 4541560
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.